|
|
Exchange: |
Nasdaq Small Cap |
Security
Type: |
Common |
Shares
Out: |
55,839,000 |
Market
Cap: |
2.38(B) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$37.92 - $61.8 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Health Services |
Level
III Sector: |
Medical Laboratories & Research |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : 1139 |
Guru Rank Value : 0 |
Guru Occurances : 1 |
|
|
|
|
|
|
|
Company Profile Vericel is a biopharmaceutical company providing cell therapies for the sports medicine and severe burn care markets. Co.'s products include: MACI®, which is an autologous cellularized scaffold product indicated for the repair of symptomatic, full-thickness cartilage defects of the knee with or without bone involvement in adults; and Epicel®, which is a permanent skin replacement for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns comprising greater than or equal to 30% of total body surface area. Co. also holds a license for North American rights to NexoBrid®, a registration-stage biological orphan product for debridement of severe thermal burns.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
94,825 |
155,676 |
418,389 |
773,623 |
Total Sell Value |
$3,921,467 |
$7,120,879 |
$19,841,755 |
$35,051,168 |
Total People Sold |
3 |
9 |
11 |
11 |
Total Sell Transactions |
6 |
18 |
44 |
82 |
End Date |
2025-03-30 |
2024-12-27 |
2024-06-28 |
2023-06-29 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Hopper Jonathan Mark |
Chief Medical Officer |
|
2025-06-02 |
4 |
AS |
$40.09 |
$400,900 |
D/D |
(10,000) |
66,237 |
|
3% |
|
Hopper Jonathan Mark |
Chief Medical Officer |
|
2025-06-02 |
4 |
OE |
$18.00 |
$180,000 |
D/D |
10,000 |
76,237 |
|
- |
|
Colangelo Dominick |
President and CEO |
|
2025-05-15 |
4 |
AS |
$41.53 |
$584,036 |
D/D |
(14,063) |
260,354 |
|
1% |
|
Colangelo Dominick |
President and CEO |
|
2025-05-15 |
4 |
OE |
$2.65 |
$37,267 |
D/D |
14,063 |
274,417 |
|
- |
|
Colangelo Dominick |
President and CEO |
|
2025-05-14 |
4 |
AS |
$42.25 |
$594,120 |
D/D |
(14,062) |
260,354 |
|
-1% |
|
Colangelo Dominick |
President and CEO |
|
2025-05-14 |
4 |
OE |
$2.65 |
$37,264 |
D/D |
14,062 |
274,416 |
|
- |
|
Mclaughlin Kevin F |
|
|
2025-05-07 |
4 |
AS |
$39.98 |
$279,860 |
D/D |
(7,000) |
15,100 |
|
3% |
|
Mclaughlin Kevin F |
|
|
2025-05-07 |
4 |
OE |
$2.76 |
$19,320 |
D/D |
7,000 |
22,100 |
|
- |
|
Mclaughlin Kevin F |
|
|
2025-04-30 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,200 |
15,100 |
|
- |
|
Wright Lisa |
|
|
2025-04-30 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,200 |
12,651 |
|
- |
|
Wotton Paul K |
|
|
2025-04-30 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,200 |
30,602 |
|
- |
|
Hagen Heidi |
|
|
2025-04-30 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,200 |
31,850 |
|
- |
|
Rubino Alan L |
|
|
2025-04-30 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,200 |
45,994 |
|
- |
|
Zerbe Robert L Md |
|
|
2025-04-30 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,200 |
29,795 |
|
- |
|
Colangelo Dominick |
President and CEO |
|
2025-04-10 |
4 |
AS |
$41.89 |
$1,040,967 |
D/D |
(24,850) |
260,354 |
|
-0% |
|
Colangelo Dominick |
President and CEO |
|
2025-04-10 |
4 |
OE |
$2.75 |
$68,338 |
D/D |
24,850 |
285,204 |
|
- |
|
Colangelo Dominick |
President and CEO |
|
2025-04-09 |
4 |
AS |
$41.11 |
$1,021,584 |
D/D |
(24,850) |
260,354 |
|
-6% |
|
Colangelo Dominick |
President and CEO |
|
2025-04-09 |
4 |
OE |
$2.75 |
$68,338 |
D/D |
24,850 |
285,204 |
|
- |
|
Hopper Jonathan Mark |
Chief Medical Officer |
|
2025-03-03 |
4 |
AS |
$49.53 |
$495,300 |
D/D |
(10,000) |
66,101 |
|
-16% |
|
Hopper Jonathan Mark |
Chief Medical Officer |
|
2025-03-03 |
4 |
OE |
$18.00 |
$180,000 |
D/D |
10,000 |
76,101 |
|
- |
|
Hagen Heidi |
|
|
2025-03-03 |
4 |
AS |
$49.53 |
$445,770 |
D/D |
(9,000) |
28,650 |
|
-16% |
|
Hagen Heidi |
|
|
2025-03-03 |
4 |
OE |
$3.74 |
$33,660 |
D/D |
9,000 |
37,650 |
|
- |
|
Mara Joseph Anthony Jr |
Chief Financial Officer |
|
2025-03-03 |
4 |
AS |
$49.53 |
$445,770 |
D/D |
(9,000) |
13,967 |
|
-16% |
|
Halpin Michael |
Chief Operating Officer |
|
2025-03-03 |
4 |
AS |
$49.52 |
$495,200 |
D/D |
(10,000) |
15,539 |
|
-16% |
|
Halpin Michael |
Chief Operating Officer |
|
2025-03-03 |
4 |
OE |
$16.66 |
$166,600 |
D/D |
10,000 |
25,359 |
|
- |
|
444 Records found
|
|
Page 1 of 18 |
|
|